Zimmer Biomet Appoints New President and CEO

Zimmer Biomet Holdings Inc., a global leader in musculoskeletal healthcare, has appointed Bryan C. Hanson as president and CEO and a member of the Board of Directors, effective today.  Daniel P. Florin, who has served as interim CEO since July 11, will continue in his role as senior vice president and chief financial officer.
 
Board Chairman Larry C. Glasscock stated, “On behalf of the board, I am thrilled to welcome Bryan to the Zimmer Biomet team. The Board of Directors, with the assistance of a leading executive search firm, carefully identified, evaluated and interviewed a number of highly-qualified candidates and concluded that Bryan is the best fit to lead the company. Bryan is a proven executive with a track record of successfully leading, growing and transforming global medical device businesses to achieve higher levels of innovation, commercial success and profitability. This leadership announcement comes at an important time in Zimmer Biomet’s history, and we look forward to working closely with Bryan to further leverage our leading portfolio of technologies, solutions and personalized services to enhance stockholder value.”
 
Hanson joins Zimmer Biomet with more than 20 years of experience in the medical device industry. Most recently, he served as a member of Medtronic’s Executive Committee and as the executive vice president and president of Medtronic’s Minimally Invasive Therapies Group, where he oversaw and provided strategic direction to this approximately $9 billion business. Medtronic replaced Hanson with Bob White, who previously was president of Medtronic’s Asia Pacific Region.

Prior to Medtronic, Hanson served in a number of executive roles of increasing responsibility. In 2013, he was named group president of Covidien’s Medical Devices business. In 2011, as Surgical Solutions Group president, Hanson transformed two of Covidien’s largest divisions—Energy-based Devices and Surgical Devices—into one global business unit. Hanson also serves on the board of AmeriCares, an emergency response and global health organization committed to saving lives and building healthier futures for people in crisis.
 
“I am honored and excited to join the talented team at Zimmer Biomet. I have long admired Zimmer Biomet, including its brand, commercial excellence and salesforce, portfolio of marquee products and strong innovation pipeline,” Hanson said. “I share the company’s purpose of improving the quality of life for patients and I look forward to deeply familiarizing myself with Zimmer Biomet’s global operations to ensure we have the right foundation in place to support our customers and the patients they serve around the world, while driving sustained shareholder value.”
 
“It has been a privilege to lead the Zimmer Biomet organization as Interim CEO. I join the rest of the management team in welcoming Bryan, and I am confident the company will thrive under his leadership,” Florin said.
 
Glasscock added, “On behalf of everyone at Zimmer Biomet, I want to thank Dan for serving as the company’s interim CEO for the past five months. We are grateful that Dan assumed this role at such an important time, and we look forward to continuing to benefit from his expertise through his ongoing service as CFO.”
 
Founded in 1927 and headquartered in Warsaw, Ind., Zimmer Biomet is a global leader in musculoskeletal healthcare. The company designs, manufactures, and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Zimmer Biomet has operations in more than 25 countries around the world and sell products in more than 100 countries.